RET and non-small cell lung carcinoma: In an international multicenter study including 165 patients with RET fusion-positive NSCLC, 53 were treated with one or more mTKIs, resulting in a median progression-free survival (PFS) of merely 2.3 months and a median OS of 6.8 months (10).